KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2025)

CRISPR Therapeutics AG's FCF Margin history spans 11 years, with the latest figure at 10771.99% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1063600.0% year-over-year to 10771.99%; the TTM value through Dec 2025 reached 9855.5%, down 947246.0%, while the annual FY2025 figure was 9855.5%, 947246.0% down from the prior year.
  • FCF Margin for Q4 2025 was 10771.99% at CRISPR Therapeutics AG, down from 9528.46% in the prior quarter.
  • Across five years, FCF Margin topped out at 21633.13% in Q1 2024 and bottomed at 2426616.67% in Q4 2022.
  • The 5-year median for FCF Margin is 10771.99% (2025), against an average of 143266.12%.
  • The largest annual shift saw FCF Margin plummeted -242587846bps in 2022 before it skyrocketed 242656893bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 738.2% in 2021, then plummeted by -328619bps to 2426616.67% in 2022, then skyrocketed by 100bps to 47.73% in 2023, then tumbled by -185bps to 136.0% in 2024, then crashed by -7821bps to 10771.99% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's FCF Margin are 10771.99% (Q4 2025), 9528.46% (Q3 2025), and 12779.93% (Q2 2025).